Bimekizumab治疗斑块状银屑病三年患者报告结局:BE RADIANT随机临床试验及开放标签扩展
BE RADIANT试验纳入373例bimekizumab和370例secukinumab随机治疗的中重度斑块状银屑病患者,双盲48周后进入96周开放标签扩展。Bimekizumab组在第4周和第1年的瘙痒、皮肤疼痛、脱屑完全缓解率及PASI=0且DLQI 0/1同时达标率均高于secukinumab组,开放标签扩展至第3年高应答率维持,secukinumab换用bimekizumab后应答提升。
要点
- Bimekizumab在第4周和第1年的瘙痒、皮肤疼痛、脱屑完全缓解率均高于secukinumab。
- Bimekizumab组PASI=0且DLQI 0/1同时达标率第4周为11.5% vs 4.6%,第1年为61.7% vs 42.7%。
- 开放标签扩展至第3年,持续bimekizumab和secukinumab换用bimekizumab患者的高应答率均维持。
核心结论
- Bimekizumab快速且持久改善中重度斑块状银屑病患者症状和健康相关生活质量至3年。
- Secukinumab随机组患者换用bimekizumab后患者报告结局改善。
研究设计与样本
- BE RADIANT为多中心3b期随机临床试验及开放标签扩展,双盲48周,开放标签扩展96周,总治疗3年。
- 基线随机分配373例接受bimekizumab、370例接受secukinumab;分别有336例和318例进入开放标签扩展。
主要发现
- 第4周无瘙痒率bimekizumab组34.0% vs secukinumab组25.1%,无皮肤疼痛率74.5% vs 60.0%,无脱屑率46.1% vs 21.6%。
- 第1年无瘙痒率60.9% vs 48.1%(nominal P < .001),无皮肤疼痛率78.6% vs 70.8%(nominal P = .01),无脱屑率70.5% vs 49.7%(nominal P < .001)。
- 第4周PASI=0且DLQI 0/1同时达标率11.5% vs 4.6%(nominal P < .001),第1年61.7% vs 42.7%(nominal P < .001)。
- 开放标签扩展 entry时PASI=0且DLQI 0/1同时达标率持续bimekizumab组69.2%,secukinumab/bimekizumab组48.5%。
- 第3年PASI=0且DLQI 0/1同时达标率持续bimekizumab组62.2%,secukinumab/bimekizumab组63.8%。
关键数值与推荐
- 持续bimekizumab组:bimekizumab 320 mg 每4周至第16周,之后每4周或每8周至1年并进入开放标签扩展。
- Secukinumab/bimekizumab组:secukinumab 300 mg 每4周至1年,之后换用bimekizumab 320 mg 每4周或每8周。
- 所有患者至第64周均接受bimekizumab每8周。
临床怎么用
- Bimekizumab治疗中重度斑块状银屑病可快速改善瘙痒、皮肤疼痛和脱屑等患者报告症状。
- 临床疗效改善可转化为健康相关生活质量提升,且可持续至3年。
- Secukinumab应答不佳者换用bimekizumab后患者报告结局可进一步改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits. OBJECTIVE: To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients). INTERVENTIONS: Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64. MAIN OUTCOMES AND MEASURES: Patient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years). RESULTS: A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03536884.
引用
- Augustin M, Feldman SR, Warren RB, et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. 2026. PMID: 41706476. doi:10.1001/jamadermatol.2025.6055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。